Lv5
890 积分 2021-09-15 加入
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial
7天前
已完结
Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer
15天前
已完结
Dominant TCRB-V-J chain usage and clonal expansion of sarcoma-reactive CD4+ HLA-DR-restricted T cells suggest a limited set of immunodominant sarcoma antigens
26天前
已完结
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
1个月前
已完结
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
1个月前
已完结
Androgen receptor splicing variant 7 (ARv7) promotes DNA damage response in prostate cancer cells
1个月前
已完结
Prevalence and Spectrum of AR Ligand-Binding Domain Mutations Detected in Circulating-Tumor DNA Across Disease States in Men With Metastatic Castration-Resistant Prostate Cancer
1个月前
已完结
PARG inhibition limits HCC progression and potentiates the efficacy of immune checkpoint therapy
2个月前
已完结
Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicase
2个月前
已完结
皖公网安备34019202002308
